ライフサイエンスコーパス: venlafaxine

1 nged from 0.72 (norfluoxetine) to 1310 ng/L (venlafaxine).

2 e and 2461 adults receiving extended-release venlafaxine.

3 roduced larger effects than extended-release venlafaxine.

4 toms and produces fewer adverse effects than venlafaxine.

5 ne, fluvoxamine, paroxetine, reboxetine, and venlafaxine.

6 d 8 weeks of treatment with extended-release venlafaxine.

7 gnificant increase in suicidal ideation with venlafaxine.

8 tcome 8 weeks later following treatment with venlafaxine.

9 ine, paroxetine, reboxetine, sertraline, and venlafaxine.

10 icating that acupuncture was as effective as venlafaxine.

11 ially involved in the mechanism of action of venlafaxine.

12 more likely not to tolerate extended-release venlafaxine.

13 ssion in depressed older adults treated with venlafaxine.

14 serotonin norepinephrine reuptake inhibitor venlafaxine.

15 ercent and 25.0 percent for extended-release venlafaxine.

16 re effectively reduces hot flashes than does venlafaxine.

17 aline, and 28.2 percent for extended-release venlafaxine.

18 nt and after 2 and 8 weeks of treatment with venlafaxine.

19 of venlafaxine but not from the high dose of venlafaxine.

20 y of the new extended-release formulation of venlafaxine.

21 o significantly reduced after treatment with venlafaxine.

22 lateral ultrabrief pulse ECT, augmented with venlafaxine.

23 , nortriptyline, paroxetine, sertraline, and venlafaxine.

24 scitalopram, sertraline, or extended-release venlafaxine.

25 ndomized controlled trials of fluoxetine and venlafaxine.

26 orhynchus mykiss) were exposed to waterborne venlafaxine (0.2 and 1.0 mug/L) for 7 days.

27 oxetine initiators compared to initiators of venlafaxine (0.7/1000 person-years [PY] [95 % CI: 0.2 -

28 e cycloalkanol ethylamine scaffold, of which venlafaxine ( 1) is a member, was undertaken to develop

29 revealed that combining normetanephrine with venlafaxine (10 mg/kg, i.p.), at a dose of normetanephri

30 .1]; and posttreatment: IPT, 16.2 [7.1], and venlafaxine, 10.9 [8.6]).

31 4 weeks, during which time patients received venlafaxine 12.5 mg orally twice daily.

32 eatment with medication (fluoxetine 20 mg or venlafaxine 150 mg) or placebo.

33 enlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg).

34 cognitive behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine p

35 uid to maternal serum ratios were higher for venlafaxine: 172% (SD=91%) (N=3).

36 assigned to sertraline plus placebo (17%) or venlafaxine (19%), but the differences did not reach sig

37 r tranylcypromine was 36.9 mg (SD=18.5); for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35

38 scores at pretreatment: IPT, 22.7 [2.7], and venlafaxine, 22.4 [3.1]; and posttreatment: IPT, 16.2 [7

39 al daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 37

40 Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or

41 mg intramuscularly for a single dose versus venlafaxine 37.5 mg per day for a week, then 75 mg per d

42 a for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxin

43 nstipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo

44 riod (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg).

45 of the clinically effective antidepressant, venlafaxine (a serotonin (5-HT) and NE reuptake inhibito

46 y investigated rCBF and clinical response to venlafaxine, a novel antidepressant.

47 selective serotonin reuptake inhibitor, and venlafaxine, a serotonin-norepinephrine reuptake inhibit

48 Venlafaxine, a serotonin-norepinephrine reuptake inhibit

49 Venlafaxine, a widely prescribed antidepressant, is a se

50 Embryonic exposure to venlafaxine accelerated early development, increased hat

51 Platelet 5-HT uptake was inhibited by venlafaxine across the dose range and by sertraline but

52 Chronic venlafaxine administration (14 days, 10 mg/kg, s.c.) eli

53 scitalopram, sertraline, or extended-release venlafaxine (all substrates for P-glycoprotein) in a lar

54 Venlafaxine also increased the transcript levels of gene

55 for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release v

56 e was no difference in response rate between venlafaxine and a second SSRI (48.2%; 95% CI, 41%-56% vs

57 ve disorder conducted by the manufacturer of venlafaxine and desvenlafaxine completed by March 2011.

58 es were observed on these parameters between venlafaxine and either sertraline plus placebo or sertra

59 athing and hypnosis, and medications such as venlafaxine and gabapentin.Additional information is ava

60 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder

61 combination treatment with extended-release venlafaxine and mirtazapine in patients with treatment-r

62 of dietary restrictions, and ease of use of venlafaxine and mirtazapine suggest that this combinatio

63 at inhibiting both uptake 1 and uptake 2 via venlafaxine and normetanephrine, respectively, elicits a

64 The relationship of venlafaxine and of benzodiazepines to self-harm events r

65 lure among duloxetine initiators compared to venlafaxine and possibly SSRIs, but not untreated patien

66 SSRI was just as efficacious as a switch to venlafaxine and resulted in fewer adverse effects.

67 fferences did not reach significance between venlafaxine and sertraline plus placebo or sertraline pl

68 der, soy protein powder and placebo pill, or venlafaxine and soy protein powder.

69 The IQs of the venlafaxine and SSRI groups were significantly lower tha

70 could explain the delayed onset of action of venlafaxine and the rapid onset of action but lack of lo

71 (N=37) were enrolled into a 12-week trial of venlafaxine and underwent five functional magnetic reson

72 hedrine and pseudoephedrine), antidepressant venlafaxine, and beta-blocker atenolol.

73 essants (citalopram, paroxetine, sertraline, venlafaxine, and bupropion, and their metabolites norflu

74 Patients given imipramine, venlafaxine, and duloxetine had more discontinuations du

75 e serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger th

76 Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more effi

77 The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorde

78 hot flash scores were reduced by 55% in the venlafaxine arm versus 79% in the MPA arm (P < .0001).

79 ndomized trials of bupropion, sertraline, or venlafaxine as an adjunct to a mood stabilizer.

80 (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes.

81 trabrief pulse ECT, combined with open-label venlafaxine at seven academic medical centers.

82 Collectively, our results demonstrate that venlafaxine, at environmentally realistic levels, is a n

83 e, but not the delayed-onset antidepressant, venlafaxine, attenuated the previously acquired FG7142-i

84 d several of the newer antidepressants, with venlafaxine being the best studied to date.

85 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasid

86 rotiline from sertraline and the low dose of venlafaxine but not from the high dose of venlafaxine.

87 Venlafaxine but not ketamine induced a positive bias whe

88 uggested that newer antidepressants, such as venlafaxine, can diminish hot flashes.

89 typical (fluoxetine, citalopram, reboxetine, venlafaxine, clomipramine) and atypical antidepressants

90 ditional treatment effect for sertraline and venlafaxine compared with fluoxetine.

91 low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem.

92 We tested the hypothesis that venlafaxine deposition in the egg, mimicking maternal tr

93 Overall, zygotic exposure to venlafaxine disrupts early development, including brain

94 children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women

95 Venlafaxine (Effexor), the therapy of choice for these s

96 ale total scores at end point were -51.7 for venlafaxine ER and -43.9 for placebo (P = .006).

97 Remission rates were 50.9% for venlafaxine ER and 37.5% for placebo (P = .01).

98 nse rates were significantly greater for the venlafaxine ER and paroxetine groups (58.6% and 62.5%, r

99 The venlafaxine ER group also showed significantly greater i

100 mprovement was significantly greater for the venlafaxine ER group than for the placebo group in clust

101 Venlafaxine ER is effective in the short-term treatment

102 Venlafaxine ER treatment was significantly superior to p

103 The mean maximum daily dose of venlafaxine ER was 221.5 mg/d.

104 In this study, venlafaxine ER was effective and well tolerated in short

105 However, the subordinate fish from the venlafaxine-exposed group had significantly higher plasm

106 The venlafaxine-exposed larvae were less active and covered

107 Venlafaxine exposure decreased the offspring number of F

108 ot achieve remission during a pre-trial with venlafaxine extended-release (150-300 mg/day) were rando

109 pressant drugs (escitalopram, sertraline, or venlafaxine extended-release).

110 nin-specific reuptake inhibitors [SSRI]), or venlafaxine-extended release (serotonin and norepinephri

111 serotonin-norepinephrine reuptake inhibitor, venlafaxine-extended release (XR).

112 n randomized to escitalopram, sertraline, or venlafaxine-extended release, and were assessed using th

113 treatment ADMs: escitalopram, sertraline or venlafaxine-extended release.

114 ts) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot fl

115 Although treatment with venlafaxine for MDD symptoms has been shown to reduce de

116 lectroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geriatric depression.

117 The venlafaxine group experienced 18 incidences of adverse e

118 By 2 weeks post-treatment, the venlafaxine group experienced significant increases in h

119 In a pooled analysis, the extended-release venlafaxine group showed a significantly greater mean de

120 with statistical parametric mapping 96, the venlafaxine group showed right posterior temporal and ri

121 The extended-release venlafaxine group showed statistically significant impro

122 levels were observed in the extended-release venlafaxine group.

123 sits, earlier year of study, and study drug (venlafaxine>desvenlafaxine).

124 equate separation of isomeric metabolites of venlafaxine, haloperidol, or adatanserin.

125 We hypothesized that venlafaxine hydrochloride and interpersonal psychotherap

126 or longer were randomly assigned to receive venlafaxine hydrochloride ER (75-225 mg/d), paroxetine (

127 n daily doses were 201.7 mg (SD, 38.1 mg) of venlafaxine hydrochloride ER and 46.0 mg (SD, 7.9 mg) of

128 Evidence indicates that venlafaxine hydrochloride extended release (ER) effectiv

129 Venlafaxine hydrochloride extended release (with doses o

130 se major depression had failed to remit with venlafaxine hydrochloride monotherapy, 91 received aripi

131 45 years received either 75 mg or 375 mg of venlafaxine hydrochloride per day, the 5-HT uptake inhib

132 ct evidence suggests that the antidepressant venlafaxine hydrochloride selectively inhibits serotonin

133 Extended-release venlafaxine hydrochloride was started at 37.5 mg/d and i

134 e, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride) are associated with lower sui

135 ine hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride.

136 Fifteen patients took 37.5 mg twice-daily of venlafaxine hydrochloride.

137 pose the midbrain region as a key target for venlafaxine impact and the mode of action involves abnor

138 Soy protein, but not venlafaxine, improved measures of QoL.

139 otion regulation, it remains unclear whether venlafaxine improves specific attentional functions.

140 to predict the likelihood of remission with venlafaxine in older adults with major depression.

141 ed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety diso

142 tive control before and after treatment with venlafaxine in patients with MDD compared to untreated h

143 safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized an

144 , randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or

145 uloxetine initiators, 21,000 were matched to venlafaxine initiators, 28,479 to SSRI initiators, and 2

146 Venlafaxine is an effective non-hormonal treatment for h

147 Venlafaxine is the first antidepressant in a new drug cl

148 ilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and highly effective tr

149 Extended-release venlafaxine may be an effective, well-tolerated short-te

150 Sertraline, unlike venlafaxine, may turn out to be a true environmental thr

151 groups improved substantially, more so with venlafaxine (mean [SD] HAM-D scores at pretreatment: IPT

152 uracy 59.7%, p=0.023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51.4%, p=

153 ceived a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks.

154 39), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and

155 studies in which either fluoxetine (N=24) or venlafaxine (N=27) was the active medication.

156 elease bupropion [N=28], or extended-release venlafaxine [N=31]).

157 aracteristics have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

158 Neither venlafaxine nor soy protein alone or in combination had

159 In androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot fla

160 Several compounds (citalopram, venlafaxine, O-desmethyl-venlafaxine) were not attenuate

161 iting uptake 2 alone, or in conjunction with venlafaxine, on extracellular levels of NE and 5-HT.

162 ained-release bupropion, or extended-release venlafaxine or an augmentation with sustained-release bu

163 which survivors of breast cancer were given venlafaxine or placebo for control of hot flashes.

164 ase who initiated duloxetine to comparators (venlafaxine or selective serotonin reuptake inhibitors [

165 inhibition of 87% or more in subjects taking venlafaxine or sertraline.

166 a medication switch alone (alternate SSRI or venlafaxine) or a medication switch plus cognitive-behav

167 clonazepam), a switch to up to 225 mg/day of venlafaxine, or prolonged sertraline treatment with plac

168 ned to sertraline plus clonazepam, switch to venlafaxine, or sertraline plus placebo.

169 mechanisms of action sequentially engaged by venlafaxine over its clinically relevant dose range.

170 In an intention-to-treat analysis, 46% of venlafaxine patients (50 of 109) compared with 74% of th

171 We tested the hypothesis that venlafaxine perturbs brain monoamine levels and disrupts

172 o venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cognitive behavioral therapy.

173 andomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus contin

174 nal ECT [STABLE] algorithm, while continuing venlafaxine plus lithium).

175 mized treatment arms: a medication only arm (venlafaxine plus lithium, over 24 weeks) and an ECT plus

176 r tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51).

177 the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).

178 anylcypromine group and the extended-release venlafaxine plus mirtazapine group, and the rates were n

179 Immediate-release venlafaxine produced larger effects than extended-releas

180 enes, which were tested for association with venlafaxine remission (a MADRS score </=10) and changes

181 Venlafaxine resulted in a weaker degree of improvement a

182 hese results demonstrate that treatment with venlafaxine selectively normalizes the executive control

183 compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor

184 ta from unpublished trials of citalopram and venlafaxine show unfavourable risk-benefit profiles.

185 mazepine (SMD, -1.57 [CrI, -2.83 to -0.31]), venlafaxine (SMD, -1.53 [CrI, -2.41 to -0.65]), duloxeti

186 The children exposed to venlafaxine, SSRIs, and maternal depression during pregn

187 .60) and continuation trials (ratio=3.75) of venlafaxine than in the acute and continuation trials of

188 curring dry mouth in patients who were given venlafaxine than in those given placebo (week 1 [baselin

189 significantly greater with extended-release venlafaxine than placebo (69% versus 48%).

190 frequent occurrence of skin problems during venlafaxine than SSRI treatment.

191 executive control, and after treatment with venlafaxine, the performance of the MDD group on executi

192 55% from baseline during the fourth week of venlafaxine therapy.

193 ketamine to the medial prefrontal cortex and venlafaxine to the amygdala.

194 with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine p

195 esults suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medic

196 All venlafaxine treatment started at 37.5 mg daily and gradu

197 ile there were no main effects of treatment, venlafaxine treatment was associated with a higher rate

198 nts (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic antidepressants, or no antidepre

199 eived protocolized treatment with open-label venlafaxine, up to 300 mg/day for approximately 12 weeks

200 citalopram, sertraline, and extended-release venlafaxine), using multivariable linear and logistic re

201 , citalopram (CLP; 5.45 mug/capita/day), and venlafaxine (VLF; 3.59 mug/capita/day).

202 three antidepressants included in the study, venlafaxine was associated with the highest relative ris

203 tinuation of treatment with extended-release venlafaxine was compared with the rate associated with d

204 single randomized studies, extended-release venlafaxine was more efficacious than paroxetine, lithiu

205 A trial of venlafaxine was performed with seven patients referred w

206 Venlafaxine was started during the first week of treatme

207 Venlafaxine was the predominant antidepressant observed

208 pounds (citalopram, venlafaxine, O-desmethyl-venlafaxine) were not attenuated.

209 ent ranged from 3 (duloxetine) to 2190 ng/L (venlafaxine), whereas individual concentrations in the w

210 e) were microinjected with either 1 or 10 ng venlafaxine, which led to a rapid reduction (90%) of thi

211 limbic blood flow increase with IPT yet not venlafaxine, while both treatments demonstrated increase

212 omized to a switch to either another SSRI or venlafaxine, with or without cognitive behavior therapy.

213 er selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therap

214 onded better and had fewer side effects with venlafaxine, with the better response most apparent for

215 bo (32.4%) were lower than after 6 months on venlafaxine XR (53.7%) (P < .03).

216 were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks.

217 Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks.

218 rates in phase 2 (months 6-12) were 9.8% on venlafaxine XR and 53.7% on placebo (P < .001).

219 evealed a significant difference between the venlafaxine XR and placebo groups in improvement on the

220 to safeguard against assigning patients with venlafaxine XR discontinuation symptoms or temporary anx

221 ommon new or worsening adverse effect in the venlafaxine XR group compared with the placebo group ove

222 e significantly lower for one or more of the venlafaxine XR groups in four of four primary and three

223 Venlafaxine XR is an effective and well-tolerated option

224 ith venlafaxine XR, followed by double-blind venlafaxine XR or placebo for 2 relapse phases, each las

225 atment, improved patients were randomized to venlafaxine XR or placebo for 6 months.

226 tudy at 12 months were randomized to receive venlafaxine XR or placebo, and all placebo patients cont

227 All venlafaxine XR patients still in the study at 12 months

228 Participants receiving venlafaxine XR reported significantly less SCI-related d

229 After 6 months' open-label venlafaxine XR treatment, improved patients were randomi

230 Twelve-week trial of venlafaxine XR vs placebo using a flexible-dose algorith

231 Venlafaxine XR was well tolerated by most patients and a

232 All doses of venlafaxine XR were well tolerated.

233 Six months' open-label treatment with venlafaxine XR, followed by double-blind venlafaxine XR

234 to respond after 12 weeks of treatment with venlafaxine XR.

235 a differential moderator of non-response to venlafaxine-XR (Cohen's d effect size 1.5; classificatio

236 Non-responders to venlafaxine-XR showed pre-treatment hyper-reactivity, wh